Evidence map›Paper›PMID 41526629›Full record

ArticleNPJ digital medicine2026

AI-guided personalized predictions on myopia progression and interventions.

Sian Liu, Yuxing Lu, Xiaoman Li, Xiaoniao Chen, Zhuo Sun, Gen Li, Kai Wang, Wei Wu, Hui Xu, Hongyi Li and 9 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sian Liu *State Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Yuxing Lu *State Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Xiaoman Li *State Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Xiaoniao Chen *State Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China. 1525980867@qq.com.
Zhuo Sun *State Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Gen Li *State Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Kai WangState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Wei WuDepartment of Big Data and Biomedical AI, College of Future Technology, Peking University, Beijing, China.
Hui XuState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Hongyi LiState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Changxi HuState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Zixing ZouState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Miao ZhangDepartment of Optometry, Shenzhen Eye Hospital, Southern Medical University, Shenzhen, China.
Xuan ZhangState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Wenyang LuState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China.
Yun YinFaculty of Business and Wellness, City University of Macau, Macau, China. jiechen@eye.ac.cn.
Jia QuState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China. jia.qu@eye.ac.cn.
Kang ZhangState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China. kang.zhang@gmail.com.
Jie ChenState Key Laboratory of Eye Health, Institute for Advanced Study on Eye Health and Diseases, Institute for Clinical Data Science, Wenzhou Medical University, Wenzhou, China. jennyyin629@gmail.com.

Funding

Beijing Nova Program 20230484246Guangzhou National Laboratory YW-SLJC0201Macau Science and Technology Development Fund, Macao 0007/2020/AFJNational Natural Science Foundation of China 32371035
6 · The paper itself

Abstract

Myopia is a major global health concern. To enable precision myopia management, we developed a Transformer-based artificial intelligence (AI) model, the Myopia Progression Predictive Model (MPPM), comprising two modules: the Natural Progression Module (NPM) for predicting untreated myopia progression and the Intervention Progression Module (IPM) for forecasting progression under specific interventions. NPM was trained on 1,109,827 refractive records from 304,353 children and adolescents, achieving high predictive accuracy for future spherical equivalent (SE) and axial length (AL) over a 10-year period. In the internal test set, SE prediction reached R² = 0.94, MAE = 0.35D; for AL, R² = 0.91, MAE = 0.16 mm. Comparable performance was observed in external validation. IPM was trained on four intervention cohorts (0.01% atropine, orthokeratology, peripheral defocus spectacles, and repeated low-level red light [RLRL] therapy) using a Transformer-based causal machine learning framework, enabling individualized estimation of treatment effects. It accurately predicted myopia changes under each intervention (SE: R² > 0.88, MAE < 0.45D; AL: R² > 0.80, MAE < 0.31 mm). Among the interventions, RLRL slightly reversed myopia progression, whereas the others slowed myopia progression. MPPM demonstrates strong promise as an AI-driven platform for personalized prediction and optimization of pediatric myopia management.

Identifiers

PMID41526629
PMCPMC12881446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.